#METABOLOMICS WORKBENCH Andre_Gollowitzer_20240705_020100 DATATRACK_ID:4978 STUDY_ID:ST003319 ANALYSIS_ID:AN005433 PROJECT_ID:PR002065
VERSION             	1
CREATED_ON             	July 14, 2024, 12:02 pm
#PROJECT
PR:PROJECT_TITLE                 	Changes in phospholipid fatty acid composition under cytotoxic stress facilitate
PR:PROJECT_TITLE                 	peroxidation
PR:PROJECT_SUMMARY               	Programs leading to cell death, such as apoptosis, necroptosis, and ferroptosis,
PR:PROJECT_SUMMARY               	involve an oxidative component linked to lipid metabolism that influences
PR:PROJECT_SUMMARY               	membrane homeostasis. Emerging evidence suggests inter-program cross-talk,
PR:PROJECT_SUMMARY               	emphasizing the need for overarching regulatory mechanisms. We show that under
PR:PROJECT_SUMMARY               	specific cytotoxic stress conditions, exogenous or released polyunsaturated
PR:PROJECT_SUMMARY               	fatty acids (PUFAs) are channeled into overall depleting phospholipids that
PR:PROJECT_SUMMARY               	become vulnerable to peroxidation in the presence of associated redox stress. In
PR:PROJECT_SUMMARY               	fibroblasts, this reprogramming results from reduced growth factor receptor
PR:PROJECT_SUMMARY               	tyrosine kinase (RTK) and phosphatidylinositol-3-kinase (PI3K)/Akt signaling,
PR:PROJECT_SUMMARY               	which reduces de novo fatty acid biosynthesis by mechanisms that differ
PR:PROJECT_SUMMARY               	depending on the specific cytotoxic stressors. We conclude that alterations in
PR:PROJECT_SUMMARY               	PUFA metabolism during cytotoxic stress render cells prone to oxidative
PR:PROJECT_SUMMARY               	modifications in phospholipids.
PR:INSTITUTE                     	University of Innsbruck
PR:DEPARTMENT                    	Michael Popp Institute
PR:LAST_NAME                     	Koeberle
PR:FIRST_NAME                    	Andreas
PR:ADDRESS                       	Mitterweg 24, Innsbruck, Tyrol, 6020, Austria
PR:EMAIL                         	andreas.koeberle@uibk.ac.at
PR:PHONE                         	+43 512 507 57903
PR:FUNDING_SOURCE                	Austrian Science Fund (FWF) (P 36299). German Research Council (GRK 1715 and KO
PR:FUNDING_SOURCE                	4589/4-1), the Phospholipid Research Center Heidelberg (AKO-2015-037/1-1,
PR:FUNDING_SOURCE                	AKO-2019-070/2-1, AKO-2O22-100/2-2), the University of Jena (DRM/2013-05 and
PR:FUNDING_SOURCE                	2.7-05).
PR:CONTRIBUTORS                  	André Gollowitzer, Helmut Pein, Konstantin Loeser, Maria Thuermer, and Andreas
PR:CONTRIBUTORS                  	Koeberle
#STUDY
ST:STUDY_TITLE                   	Changes in the phosphatidylcholine fatty acid composition in subcellular
ST:STUDY_TITLE                   	fractions of fibroblasts induced by valinomycin
ST:STUDY_SUMMARY                 	Determination of the impact of valinomycin on the subcellular
ST:STUDY_SUMMARY                 	phosphatidylcholine fatty acid composition of NIH-3T3 fibroblasts challenged
ST:STUDY_SUMMARY                 	with valinomycin for 48 h and disrupted by repeated passage through a syringe.
ST:STUDY_SUMMARY                 	Nuclear, mitochondrial, membrane, and cytosolic fractions were obtained by
ST:STUDY_SUMMARY                 	differential centrifugation.
ST:INSTITUTE                     	University of Innsbruck
ST:DEPARTMENT                    	Michael Popp Institute
ST:LAST_NAME                     	Koeberle
ST:FIRST_NAME                    	Andreas
ST:ADDRESS                       	Mitterweg 24, Innsbruck, Tyrol, 6020, Austria
ST:EMAIL                         	andreas.koeberle@uibk.ac.at
ST:PHONE                         	+43 512 507 57903
#SUBJECT
SU:SUBJECT_TYPE                  	Cultured cells
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	180208_nucleus_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180208_nucleus_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=10 µM
SUBJECT_SAMPLE_FACTORS           	-	180222_nucleus_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180222_nucleus_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=10 µM
SUBJECT_SAMPLE_FACTORS           	-	180405_nucleus_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180205_nucleus_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_nuclei; concentration=10 µM
SUBJECT_SAMPLE_FACTORS           	-	180208_membrane_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180208_membrane_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=10 µM
SUBJECT_SAMPLE_FACTORS           	-	180222_membrane_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180222_membrane_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=10 µM
SUBJECT_SAMPLE_FACTORS           	-	180405_membrane_DMSO	Sample source:cultured cells | treatment:vehicle	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=-
SUBJECT_SAMPLE_FACTORS           	-	180205_membrane_Valinomycin	Sample source:cultured cells | treatment:VAL	RAW_FILE_NAME(Local_data_file)=180724_apoptosis_SCF_membrane; concentration=10 µM
#COLLECTION
CO:COLLECTION_SUMMARY            	To separate (peri)nuclear from non-nuclear membranes, NIH-3T3 fibroblasts were
CO:COLLECTION_SUMMARY            	suspended in 500 µl ice-cold hypotonic fractionation buffer (10 mM HEPES pH
CO:COLLECTION_SUMMARY            	7.4, 2 mM MgCl2, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM dithiothreitol) and
CO:COLLECTION_SUMMARY            	passed through a 25-gauge needle ten times. After 45 min on ice, the
CO:COLLECTION_SUMMARY            	(peri)nuclear (pellet) and non-nuclear fractions (supernatant) were separated by
CO:COLLECTION_SUMMARY            	centrifugation (600×g, 10 min, 4°C). Non-nuclear membranes were obtained from
CO:COLLECTION_SUMMARY            	the supernatant by centrifugation (100.000×g, 1 h, 4°C). The remaining intact
CO:COLLECTION_SUMMARY            	cells in the (peri)nuclear fraction were disrupted by repeated homogenization in
CO:COLLECTION_SUMMARY            	fractionation buffer (500 µl). Pellets were washed with PBS pH 7.4 prior to
CO:COLLECTION_SUMMARY            	analysis by UPLC-MS/MS and Western Blot.
CO:SAMPLE_TYPE                   	Fibroblasts
CO:COLLECTION_METHOD             	Trypsinization of cultured cells
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	NIH-3T3 fibroblasts were cultivated in DMEM high glucose medium containing
TR:TREATMENT_SUMMARY             	heat-inactivated fetal calf serum (FCS, 10%). After cultivation for 24 h, cells
TR:TREATMENT_SUMMARY             	were treated with vehicle or VAL (10 µM).
TR:TREATMENT_VEHICLE             	DMSO
TR:CELL_MEDIA                    	DMEM + 10% FCS
TR:CELL_ENVIR_COND               	37°C, 5% CO2
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Phospholipids were extracted from cell pellets after subcellular fractionation
SP:SAMPLEPREP_SUMMARY            	by successive addition of PBS pH 7.4, methanol, chloroform, and saline to a
SP:SAMPLEPREP_SUMMARY            	final ratio of 14:34:35:17. Evaporation of the organic layer yielded a lipid
SP:SAMPLEPREP_SUMMARY            	film that was dissolved in methanol, diluted, and subjected to UPLC-MS/MS.
SP:EXTRACT_STORAGE               	-20℃
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Chromatographic separation of phospholipids was carried out on an Acquity BEH C8
CH:CHROMATOGRAPHY_SUMMARY        	column (1.7 μm, 2.1×100 mm, Waters, Milford, MA) using an Acquity
CH:CHROMATOGRAPHY_SUMMARY        	Ultraperformance LC system (Waters).
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity H-Class
CH:COLUMN_NAME                   	Waters ACQUITY UPLC BEH C8 (100 x 2.1mm,1.7um)
CH:SOLVENT_A                     	90% Water/10% Acetonitrile; 10 mM ammonium acetate
CH:SOLVENT_B                     	5% Water/95% Acetonitrile; 10 mM ammonium acetate
CH:FLOW_GRADIENT                 	The gradient was ramped from 70 to 80% B over 5 min and further increased to
CH:FLOW_GRADIENT                 	100% B within 2 min, followed by isocratic elution for another 2 min.
CH:FLOW_RATE                     	0.75 mL/min
CH:COLUMN_TEMPERATURE            	45
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	ABI Sciex 5500 QTrap
MS:INSTRUMENT_TYPE               	QTRAP
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Targeted MRM with pre-optimized settings and subsequent automated integration of
MS:MS_COMMENTS                   	selected signals using Analyst 1.6 (Sciex).
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	relative units
MS_METABOLITE_DATA_START
Samples	180208_nucleus_DMSO	180222_nucleus_DMSO	180405_nucleus_DMSO	180208_nucleus_Valinomycin	180222_nucleus_Valinomycin	180205_nucleus_Valinomycin	180208_membrane_DMSO	180222_membrane_DMSO	180405_membrane_DMSO	180208_membrane_Valinomycin	180222_membrane_Valinomycin	180205_membrane_Valinomycin
Factors	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:VAL	Sample source:cultured cells | treatment:VAL	Sample source:cultured cells | treatment:VAL	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:vehicle	Sample source:cultured cells | treatment:VAL	Sample source:cultured cells | treatment:VAL	Sample source:cultured cells | treatment:VAL
PC(14:0_16:0)	2.545146877	2.404912559	2.388990143	8.486332109	6.104423456	10.2734089	3.133331603	3.12860383	3.127101021	7.301395706	6.484086845	8.590158993
PC(16:0/16:0)	13.06967315	12.60827944	11.03279084	14.19828641	15.03596928	12.48701634	17.6134025	20.55382142	17.25768876	17.34609038	15.53164988	17.33102253
PC(16:0_16:1)	3.557309534	3.303836186	3.04053291	3.598531212	2.809115219	3.292031581	3.5226805	2.692810781	2.97074597	3.270856458	3.006806783	2.727752242
PC(16:0_18:1)	18.4744252	18.56218917	16.07138824	19.17584659	24.30965093	17.65210037	18.37355987	20.16355899	17.02315618	19.81505945	23.55382244	20.04370432
PC(16:1_18:1)	9.355134465	9.070956595	11.11966321	6.217870257	5.510187544	7.832764796	8.454433201	7.089767514	8.970871054	6.119666921	5.880915975	6.570718107
PC(16:1_18:1) iso	3.311638986	3.011977865	2.92759883	2.015503876	1.818722033	1.912783867	2.985008213	2.23750461	2.697124631	2.152434572	1.927130927	1.853665888
PC(18:0_18:1)	12.2835274	13.77571272	16.85323956	15.58547532	13.9375332	16.74395373	11.5877648	12.87866026	15.71368263	16.18546389	16.01418658	15.22115892
PC(18:1/18:1)	29.18566109	30.00303533	28.92849883	12.97429621	14.96394068	14.58710545	27.43982705	26.66793285	26.77580249	14.47617761	14.41578378	15.37186346
PC(18:1_18:2)	3.095448904	2.82518854	3.205590411	2.643818849	2.268900754	3.08202267	2.428795503	1.606580345	2.091248808	2.257946071	2.270938323	2.456484063
PC(16:0_20:3 n-6)	0.39896897	0.347895118	0.445655252	0.987352101	0.972386037	0.868415227	0.302208906	0.24651577	0.300983473	0.694265661	0.699678208	0.625423857
PC(16:0_20:3 n-9)	0.259428099	0.221812323	0.166794948	0.263565891	0.280911522	0.204900586	0.226193169	0.191228592	0.129579249	0.221574147	0.237046152	0.182352498
PC(18:0_20:3 n-6)	0.122835274	0.098181139	0.140733238	0.624235006	0.515004457	0.497777879	0.087139991	0.059710152	0.099090014	0.352408405	0.358886667	0.304423178
PC(18:0_20:3 n-9)	0.231912997	0.185621892	0.204150067	0.252957976	0.217886501	0.25087551	0.202090618	0.191228592	0.178244758	0.209756859	0.231316028	0.210986361
PC(18:1_20:3 n-6)	0.326250488	0.248663289	0.28494137	0.562219502	0.502399453	0.483020496	0.292938694	0.175618094	0.228669262	0.379841395	0.428251317	0.406902268
PC(18:1_20:3 n-9)	0.339025356	0.258002755	0.200675172	0.198286414	0.175569701	0.184467287	0.318895287	0.275135015	0.194271151	0.204270261	0.176427479	0.18838068
PC(16:0_20:4)	0.728167504	0.733148101	0.769689188	3.541411669	2.881143814	2.866337842	0.760157371	0.4279878	0.517926107	2.658889766	2.786649416	2.426343154
PC(18:0_20:4)	0.325267805	0.304700086	0.316215423	2.252141983	2.070822116	1.356544048	0.331873584	0.2887942	0.293165721	1.686073748	1.676815017	1.186044759
PC(18:1_20:4)	1.061296767	0.833547363	0.744496201	2.888616891	2.647050879	2.304422107	0.841735235	0.425386051	0.586331441	2.215741472	2.102050479	1.959159069
PC(16:0_22:5)	0.306596844	0.30936982	0.335327344	1.109751122	0.912962446	0.953553975	0.283668482	0.204237339	0.244304767	0.79766693	0.73586846	0.785170673
PC(18:0_22:5)	0.132662096	0.105769455	0.15550154	0.599755202	0.614043775	0.459181646	0.100674501	0.119680479	0.10456244	0.546549563	0.431267172	0.355662723
PC(18:1_22:5)	0.348852178	0.29185832	0.248454975	0.526315789	0.437573717	0.491534371	0.209506788	0.109273481	0.166713573	0.278550356	0.276855429	0.287845679
PC(16:0_22:6)	0.225034222	0.197296225	0.179825804	0.609547124	0.446577291	0.601647151	0.194674449	0.11187523	0.113552856	0.352408405	0.307617143	0.399367041
PC(18:0_22:6)	0.086770838	0.08207056	0.075057727	0.345981232	0.342135828	0.252578285	0.070268206	0.029855076	0.088926935	0.234235527	0.227093832	0.197422952
PC(18:1_22:6)	0.228964951	0.215975157	0.164188777	0.341901265	0.22508936	0.361555882	0.239171466	0.124233541	0.126256704	0.242676447	0.238855664	0.317986587
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	Standardized name	Exact mass	Formula	Super class	Main class	Sub class
PC(14:0_16:0)	PC 14:0_16:0	705.5309	C38H76NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0/16:0)	PC 16:0/16:0	733.5622	C40H80NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_16:1)	PC 16:0_16:1	731.5465	C40H78NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_18:1)	PC 16:0_18:1	759.5778	C42H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:1_18:1)	PC 16:1_18:1	757.5622	C42H80NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:1_18:1) iso	PC 16:1_18:1	757.5622	C42H80NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_18:1)	PC 18:0_18:1	787.6091	C44H86NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1/18:1)	PC 18:1/18:1	785.5935	C44H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_18:2)	PC 18:1_18:2	783.5778	C44H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_20:3 n-6)	PC 16:0_20:3	783.5778	C44H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_20:3 n-9)	PC 16:0_20:3	783.5778	C44H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_20:3 n-6)	PC 18:0_20:3	811.6091	C46H86NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_20:3 n-9)	PC 18:0_20:3	811.6091	C46H86NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_20:3 n-6)	PC 18:1_20:3	809.5935	C46H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_20:3 n-9)	PC 18:1_20:3	809.5935	C46H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_20:4)	PC 16:0_20:4	781.5622	C44H80NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_20:4)	PC 18:0_20:4	809.5935	C46H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_20:4)	PC 18:1_20:4	807.5778	C46H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_22:5)	PC 16:0_22:5	807.5778	C46H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_22:5)	PC 18:0_22:5	835.6091	C48H86NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_22:5)	PC 18:1_22:5	833.5935	C48H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(16:0_22:6)	PC 16:0_22:6	805.5622	C46H80NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:0_22:6)	PC 18:0_22:6	833.5935	C48H84NO8P	Glycerophospholipids	Glycerophosphocholines	PC
PC(18:1_22:6)	PC 18:1_22:6	831.5778	C48H82NO8P	Glycerophospholipids	Glycerophosphocholines	PC
METABOLITES_END
#END